This review highlights emerging noninvasive imaging techniques and artificial intelligence applications that may improve the diagnosis, characterization, and risk stratification of hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Warrants prospective validation of AI-enhanced imaging in hypertrophic cardiomyopathy; leaves open impact on routine diagnosis and risk stratification.
In this article some of the recent advances in the use of noninvasive imaging applied to patients with hypertrophic cardiomyopathy (HCM) are discussed. Echocardiography and cardiac computed tomography are briefly discussed with respect to their power to detect apical aneurysmal disease. Echocardiographic phenotype-genotype correlations and the use of echocardiography to characterize myocardial work are reviewed. Positron emission tomography is reviewed in the context of ischemia imaging and also in the context of the use of a new tracer that might allow for recognition of early activation of the fibrosis pathway. Next, the technical capabilities of cardiovascular magnetic resonance to measure myocardial perfusion, oxygenation, and disarray are discussed as they apply to HCM. The application of radiomics to improve prediction of sudden cardiac death is touched upon. Finally, a deep learning approach to the recognition of HCM vs phenocopies is presented as a potential future diagnostic aid in the not-too-distant future.
No takes yet. Share an insight, caveat, or question.
Andrew Crean (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: